Use of Atropine in Tredmill Stress Testing
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00623207 |
Recruitment Status
:
Completed
First Posted
: February 25, 2008
Last Update Posted
: July 27, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The aim of this study is to evaluate the Safety and feasibility of atropine added during treadmill stress testing in patients with chronotropic incompetence or poor exercise capacity.
Our hypothesis is that we can increase heart rate by using atropin in these patients, so we will achieve more conclusive results.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Chest Pain | Drug: Atropine | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 103 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | Safety and Feasibility of Atropine Added During Treadmill Stress Testing in Patients With Chronotropic Incompetence or Poor Exercise Capacity. |
Study Start Date : | December 2007 |
Actual Primary Completion Date : | October 2009 |
Actual Study Completion Date : | October 2009 |

Arm | Intervention/treatment |
---|---|
Placebo Comparator: 1
Pateints who achieve target haert rate or conclusive test will not be given Atropine
|
Drug: Atropine
I.V Atropine 0.5mg up to 2 mg
|
Active Comparator: 2
Patients who won't achieve tarhet heart rate or conclusive results will be given Atropine
|
Drug: Atropine
I.V Atropine 0.5mg up to 2 mg
|
- 1- To characterize patients who can't achieve target heart rate at treadmill exercise test.2- To evaluate atropine added during treadmill stress testing in order to increase heart rate and achieave conclusive test. [ Time Frame: 1 yaer ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with chest pain without evidence of ischemia eligible for exercise test.
- Age> 18 years old
Exclusion Criteria:
Absolute:
- Patients with LBBB
- Unstable Angina
- Recent Myocardial Infarction
- Un controlled Arrythmia
- Congestive heart faliure
- Severe symptomatic valvular heart disease
- Acute Pulmonary Embolism
- Acute perimyocarditis
- Acute aortic dissection
Relative:
- Lt main stenosis
- Severe hypertention (Systolic> 200 mmHg; Diastolic > 100 mmHg)
- Cardiomyopathy
- Obstructiove abnormalities
- Psychiatric disorders
- High degree AV Block

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00623207
Israel | |
Heart Institute, Ha'Emek Medical Center | |
Afula, Israel, 18100 |
Responsible Party: | Mohamed Jabaren, MD, HaEmek Medical Center, Israel |
ClinicalTrials.gov Identifier: | NCT00623207 History of Changes |
Other Study ID Numbers: |
07-0139 EMC |
First Posted: | February 25, 2008 Key Record Dates |
Last Update Posted: | July 27, 2015 |
Last Verified: | July 2015 |
Keywords provided by Mohamed Jabaren, HaEmek Medical Center, Israel:
Chest Pain Low work Capacity Rate Incompetence |
Additional relevant MeSH terms:
Chest Pain Pain Neurologic Manifestations Nervous System Diseases Signs and Symptoms Atropine Adjuvants, Anesthesia Anti-Arrhythmia Agents Bronchodilator Agents Autonomic Agents Peripheral Nervous System Agents |
Physiological Effects of Drugs Anti-Asthmatic Agents Respiratory System Agents Mydriatics Parasympatholytics Muscarinic Antagonists Cholinergic Antagonists Cholinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |